Carole Ho, MD, is the Chief Medical Officer and Head of Development at Denali Therapeutics in South San Francisco. Denali Therapeutics is dedicated to therapeutic discovery and development of treatments for neurodegenerative diseases. Prior to Denali, Dr. Ho was Vice President of Early Clinical Development at Genentech. In that role, she managed a team of medical directors responsible for delivery of pivotal trial-ready therapeutic candidates in neurology, ophthalmology, immunology, and infectious disease and served as the Chair of the Development Review Committee.
During her eight-year tenure at Genentech, she led the successful development of multiple therapeutics that advanced to Phase III trials or were approved, including ocrelizumab for multiple sclerosis, lampalizumab for age-related macular degeneration, rituxan for granulomatosis with polyangiitis and microscopic polyangiitis, and crenezumab for Alzheimer’s disease. She and her team also spearheaded the Alzheimer's Prevention Initiative with Banner Health. This was a landmark Alzheimer prevention study in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. Before joining Genentech, Dr. Ho served as a Medical Director at Johnson and Johnson and was a faculty member in the Department of Neurology at Stanford University.
Dr. Ho earned her undergraduate degree in biochemical sciences from Harvard University and her medical degree from Cornell University. She completed her medical internship and neurology residency at Harvard and served as chief resident of neurology at Brigham and Women's Hospital/Massachusetts General Hospital.